Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Aviragen's SPIRITUS trial misses endpoint
April 2017
SHARING OPTIONS:

ATLANTA—Recent top-line data from Aviragen Therapeutics' Phase 2b SPIRITUS trial of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection revealed that the compound fell short of its goal. Vapendavir did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 at day 14, the primary endpoint, for either the 264 mg or 528 mg cohorts compared to placebo.
 
“We are disappointed that the SPIRITUS trial did not meet its primary endpoint in this patient population. There was evidence of an antiviral effect in patients that received vapendavir within the first day following the onset of their symptoms, and as such, we plan to take time to fully analyze the data before making a decision on whether to initiate a study in hematopoietic stem cell transplant patients, where the ability to stop the progression of the RV infection could be beneficial,” stated Dr. Joseph Patti, president and CEO of Aviragen.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.